

SmartPA Criteria Proposal

Drug/Drug Class:	Psychotropic Medications Polypharmacy Clinical Edit
First Implementation Date:	November 5, 2010
Proposed Date:	September 17, 2020
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate and prudent use psychotropic medications

Why Issue Selected: MO HealthNet will assess the usage of psychotropic agents in the pharmacy program with a primary goal of patient safety in regard to polypharmacy or use of more drugs than is medically necessary. Participants may have multiple prescribers and/or multiple pharmacies caring for them, and, by using medical evidence guidelines, this clinical edit can flag potentially dangerous duplication within drug classes, dangerous drug interactions, or overmedication. The edit helps to provide an “early warning alert” to the pharmacist filling the prescription and the prescribing physician. As always, if a provider wishes to override a denial for medically necessary reasons, a claim can be approved with further medical input through direct communication with the MHD Hotline.

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

- Drug class for review: Psychotropic medications
- Age range: All appropriate MO HealthNet participants

- Participant ≤ 5 years of age: history of ≤ 3 different psychotropic medications in the past 60 days
- Participant ≥ 6 years of age: history of ≤ 5 different psychotropic medications in the past 60 days
- Documented diagnosis of a seizure disorder: all seizure medications are not counted in a participant's past history of psychotropic medications

Denial Criteria

- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

Default Approval Period

6 months

Appendix A – Agents in the Psychotropic Medications Polypharmacy Clinical Edit

Psychotropic Medications
ALPRAZOLAM
AMITRIPTYLINE HCL
AMITRIPTYLINE/CHLORDIAZEPOXIDE
AMOBARBITAL SODIUM
AMOXAPINE
AMPHETAMINE
AMPHETAMINE SULFATE
ARIPIPIRAZOLE
ARIPIPIRAZOLE LAUROXIL
ARMODAFINIL
ASENAPINE
ASENAPINE MALEATE
ATOMOXETINE HCL
BREXPIPIRAZOLE
BRIVARACETAM
BUPROPION HBR
BUPROPION HCL
BUSPIRONE HCL
BUTABARBITAL SODIUM
CARBAMAZEPINE
CARIPRAZINE HCL
CHLORDIAZEPOXIDE HCL
CHLORDIAZEPOXIDE/CLIDINIUM BR
CHLORPROMAZINE HCL
CITALOPRAM HYDROBROMIDE
CLOBAZAM
CLOMIPRAMINE HCL
CLONAZEPAM
CLONIDINE HCL

Psychotropic Medications continued
CLORAZEPATE DIPOTASSIUM
CLOZAPINE
DESIPRAMINE HCL
DESVENLAFAXINE
DESVENLAFAXINE FUMARATE
DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HCL
DEXTROAMPHETAMINE SULFATE
DEXTROAMPHETAMINE/AMPHETAMINE
DIAZEPAM
DIVALPROEX SODIUM
DOXEPIN HCL
DULOXETINE HCL
ESCITALOPRAM OXALATE
ESLICARBAZEPINE ACETATE
ETHOSUXIMIDE
ETHOTOIN
EZOGBINE
FELBAMATE
FLUOXETINE HCL
FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL
FLUVOXAMINE MALEATE
FOSPHENYTOIN SODIUM
GABAPENTIN
GABAPENTIN ENACARBIL
GABAPENTIN/LIDOCAINE
GUANFACINE HCL
HALOPERIDOL

SmartPA Clinical Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Psychotropic Medication continued
HALOPERIDOL DECANOATE
HALOPERIDOL LACTATE
ILOPERIDONE
IMIPRAMINE HCL
IMIPRAMINE PAMOATE
ISOCARBOXAZID
LACOSAMIDE
LAMOTRIGINE
LEVETIRACETAM
LEVETIRACETAM IN NACL (ISO-OS)
LEVOMILNACIPRAN HCL
LISDEXAMFETAMINE DIMESYLATE
LITHIUM CARBONATE
LITHIUM CITRATE
LORAZEPAM
LORAZEPAM IN 5 % DEXTROSE
LORAZEPAM/0.9% SODIUM CHLORIDE
LOXAPINE
LOXAPINE SUCCINATE
LUMATEPERONE TOSYLATE
LURASIDONE HCL
MAPROTILINE HCL
MEPROBAMATE
METHAMPHETAMINE HCL
METHSUXIMIDE
METHYLPHENIDATE
METHYLPHENIDATE HCL
MIDAZOLAM
MIDAZOLAM HCL
MILNACIPRAN HCL
MIRTAZAPINE
MODAFINIL
MOLINDONE HCL
NEFAZODONE HCL
NORTRIPTYLINE HCL
OLANZAPINE
OLANZAPINE PAMOATE
OLANZAPINE/FLUOXETINE HCL
OXAZEPAM
OXCARBAZEPINE
PALIPERIDONE
PALIPERIDONE PALMITATE
PAROXETINE HCL
PAROXETINE MESYLATE

Psychotropic Medication continued
PENTOBARBITAL SODIUM
PERAMPANEL
PERPHENAZINE
PERPHENAZINE/AMITRIPTYLINE HCL
PHENELZINE SULFATE
PHENOBARBITAL
PHENOBARBITAL SODIUM
PHENOBARBITAL/0.9 % SOD CHLOR
PHENYTOIN
PHENYTOIN SODIUM
PHENYTOIN SODIUM EXTENDED
PIMAVANSERIN TARTRATE
PIMOZIDE
PITOLISANT HCL
PREGABALIN
PRIMIDONE
PROTRIPTYLINE HCL
QUETIAPINE FUMARATE
RISPERIDONE
RISPERIDONE MICROSPHERES
RUFINAMIDE
SECOBARBITAL SODIUM
SELEGILINE
SERTRALINE HCL
SODIUM OXYBATE
SOLRIAMFETOL HCL
STIRIPENTOL
THIORIDAZINE HCL
THIOTHIXENE
TIAGABINE HCL
TOPIRAMATE
TRANLYCYPROMINE SULFATE
TRAZODONE HCL
TRIFLUOPERAZINE HCL
TRIMIPRAMINE MALEATE
VALPROIC ACID
VALPROIC ACID (AS SODIUM SALT)
VENLAFAXINE HCL
VIGABATRIN
VILAZODONE HCL
VORTIOXETINE HYDROBROMIDE
ZIPRASIDONE HCL
ZIPRASIDONE MESYLATE
ZONISAMIDE

SmartPA Clinical Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.